1.	In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ITL-002-CRYO, NCT00861107
2.	Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX1401-01, NCT00948961
3.	Pharmacokinetic Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST AVF3911s, NCT00945139
4.	UCN-01 and Irinotecan in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple-Negative Breast Cancer (Currently accruing only triple-negative breast cancer patients since 6/8/2007) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
5.	A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2007.120, NCT00637390
6.	A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 Given on a Daily Oral Regimen in Subjects With Advanced Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARRAY-380-101, NCT00650572
7.	MK4827 in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2008_501, MK4827-001, NCT00749502
8.	Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL147-003, NCT00756847
9.	Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HBS601, NCT00765973
10.	Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MI-CP177, NCT00796055
11.	Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ATDTRPST0802, NCT00800345
12.	Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
13.	Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TAMC 3H04, NCT00160472
14.	CBT-1 and Paclitaxel in Treating Patients With Refractory, Recurrent, or Advanced Metastatic Solid Tumors Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-08-C-0035, 08-C-0035, NCT00658424